|
Market Cap (4-Jul) $171,348,752 (477th) |
Close (30-Jun) $0.99 |
Volume (30-Jun) 1,077,429 |
Shortsold (19-Jun) 1,473,254 (0.38%) (338th) |
|
52w High $0.66 |
52w Low $0.165 |
P/E - |
EPS -0.05 |
PAR released this announcement to the ASX on 15 April 2021, 16:25. The announcement is not marked as price sensitive, and is 16 page(s) in length and 423.91kb in size.
You can view all announcements from PAR and see how they appear on a price chart on the announcements page.
At the date of this announcement, PAR was 4.212% short sold according to ASIC data. It was ranked the 28th most shorted stock on the ASX. It remains ranked 338th as of the latest reported data (19 June 2025).
| Other Recent Announcements from PAR | |
|---|---|
| Notification of cessation of securities - PAR | 29 June 2023, 16:43 |
| Primary and Secondary endpoints met in MPS I Trial | 6 June 2023, 12:28 |
| iPPS shows 3-year equivalent durability in OA Canine Study | 1 June 2023, 8:21 |
| Cleansing Notice and Appendix 2A | 15 April 2021, 16:25 |
| Paradigm doses first participant in Synovial Fluid Trial | 14 April 2021, 9:16 |
| Paradigm and Bene Execute New Collaboration Agreement | 31 March 2021, 8:31 |
| Paradigm delivers IND to US FDA for Pivotal OA Program | 26 March 2021, 9:40 |
You must be logged in to post a reply.
Paradigm Biopharmaceuticals 